Assessment of Prostate Cancer Radiation Therapy Using Prostate Specific Antigen

Abstract

This was an analytical study aimed evaluate radiation therapy for prostate cancer patients using PSA range, a total of 193 patients, age range 39-88 years old with mean 69.1±9.4 years prostate cancer treated with surgery(Partial+Total Removal ;partial dominant) and radical radiotherapy were included . Those patients referred to RICK RIA lab, the study variables was included PSA level, age, T-stage, marital status, family history. The data collected in a master data sheet after filling a questioner and analyzed using EXCELL software and statistical package for social science SPSS.16 in form of clustered column and curves. The result show overall 93 patients were reached references levels of PSA less than1 and 1-4ng/ml which represented 48.1 percent in mean follow up of 2months. The PSA3 (After Radiation) was (17.1 ± 24.1ng/ml) for those with PSA1(Frist) was(87 ± 48.6 ng/ml). Stage II&age group 5(64-70) years was dominant. Asignificant relation between PSA1&PSA3 was noted witht= 19.8 and p=0.000ng/ml.The PSA3 was higher in age groups1&4 (39-45.5)&(57.5-64) years with 25 &20 ng/ml respectively, While the lowest level 3.7 ng/ml in age group 2 (45.5-51.5).An inverse relation betweenPSA1& PSA3noted which was decreased by 0.38ng/ml/ng/ml. Unfortunately 100 patients were having PSA3 more than 4ng/ml represented the majority due to treatments interval and delay follow up. A data Base for PSA level after and before the treatment should be founded because that PSA consider to be A good biomarker for prostate cancer overall treatment outcome, sign for recurrent and metastatic in the body.